Breaking News

Telix’s Illucix Approved by Danish Medicines Agency

Danish physicians and their patients will now have access to Telix's gallium-based PSMA-PET imaging agent.

Author Image

By: Charlie Sternberg

Associate Editor

Image courtesy of Tung Lam from Pixabay.

Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency. Illuccix, after radiolabelling with gallium-68, is indicated in Denmark for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Suspected recurrent PCa in patients with increasing l...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters